MediciNova
MNOV
$1.31
Share price
-0.76%
Change (1 day)
-38.21%
Change (1 year)
Categories
P/S ratio for MediciNova (MNOV)
P/S ratio as of April 2024 (TTM): 64.3
According to MediciNova's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 64.2505. At the end of 2023 the company had a P/S ratio of 73.6.
P/S ratio history for MediciNova from 2006 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 73.6 | |
| 2022 | N/A | -100% |
| 2021 | 32.6 | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A | -100% |
| 2013 | 8.02 | -77.45% |
| 2012 | 35.6 | |
| 2011 | N/A | |
| 2010 | N/A | |
| 2009 | N/A | |
| 2006 | 490 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.90 | -93.93% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 20.4 | -68.23% | 🇺🇸 USA |
 Sanofi SNY | 2.44 | -96.20% | 🇫🇷 France |
 Titan Pharmaceuticals
TTNP | > 1000 | 9,533.17% | 🇺🇸 USA |
 Alkermes ALKS | 2.51 | -96.10% | 🇮🇪 Ireland |
 Teva Pharmaceutical Industries TEVA | 0.9871 | -98.46% | 🇮🇱 Israel |